Evidence map›Paper›PMID 33739368›Full record

ReviewBiology of reproduction2021

Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies†.

Abdelrahman AlAshqar, Lauren Reschke, Gregory W Kirschen, Mostafa A Borahay

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biology of reproduction, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Platelets as key cells in endometriosis patients: Insights from small extracellular vesicles in peritoneal fluid and endometriotic lesions analysis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Abdelrahman AlAshqarDepartment of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, MD, USA.
Lauren ReschkeDepartment of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, MD, USA.
Gregory W KirschenDepartment of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, MD, USA.
Mostafa A BorahayDepartment of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins University · USKuwait University · KW

Funding

Mechanisms of actions(s) of simvastatin in uterine leiomyomaR01HD094380 · NICHD · JOHNS HOPKINS UNIVERSITY · PI BORAHAY, MOSTAFA A. · 2018 to 2022
$4.0M
NICHD NIH HHS R01 HD094380
6 · The paper itself

Abstract

Emerging evidence supports the notion that inflammation fosters the development of common benign gynecologic disorders, including uterine leiomyoma, endometriosis, and adenomyosis. Numerous cytokines, chemokines, and growth and transcription factors have indisputable roles in the establishment and maintenance of benign gynecologic disorders by initiating complex cascades that promote proliferation, angiogenesis, and lesion progression. The interaction between inflammation and benign gynecologic disorders is orchestrated by a plethora of factors, including sex steroids, genetics, epigenetics, extracellular matrix, stem cells, cardiometabolic risk factors, diet, vitamin D, and the immune system. The role of inflammation in these disorders is not limited to local pathobiology but also extends to involve clinical sequelae that range from those confined to the reproductive tract, such as infertility and gynecologic malignancies, to systemic complications such as cardiovascular disease. Enhanced understanding of the intricate mechanisms of this association will introduce us to unvisited pathophysiological perspectives and guide future diagnostic and therapeutic implications aimed at reducing the burden of these disorders. Utilization of inflammatory markers, microRNA, and molecular imaging as diagnostic adjuncts may be valuable, noninvasive techniques for prompt detection of benign gynecologic disorders. Further, use of novel as well as previously established therapeutics, such as immunomodulators, hormonal treatments, cardiometabolic medications, and cyclooxygenase-2 and NF-κB inhibitors, can target inflammatory pathways involved in their pathogenesis. In this comprehensive review, we aim to dissect the existing literature on the role of inflammation in benign gynecologic disorders, including the proposed underlying mechanisms and complex interactions, its contribution to clinical sequelae, and the clinical implications this role entails.

Indexed as

FemaleGenital Diseases, FemaleHumansInflammationadenomyosischemokinecytokineendometriosisgrowth factorinfertilityinflammationprostaglandinuterine leiomyoma

Identifiers

PMID33739368
PMCPMC8256101
OpenAlexW3135997022

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.